Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review

Table 2 Comparative distribution of accessible baseline characteristics of patients among studies included in the systematic review

Characteristics	Langer n = 107 (%)		Portier n = 171 (%)		Nordlinger n = 364 (%)		Ychou n = 306 (%)		Primrose1n = 257 (%)
	Surg n = 55	S + C n = 52	Surg n = 85	S + C n = 86	Surg n = 182	S + C n = 182	S + 5-FU n = 153	S + FOLFIRI n = 153	S + C n = 128	S + C + Cetuximab n = 129
Median age	60	63.5	63	63	62	64	61	63	64	63
Gender (male)	65.4	65.4	62.4	53.5	63	70	65.4	58.8	63	71
Primary site (rectum)	30.9	26.9	40	40.7	37	46	26.1	28.8	-	-
DFI ≤ 12 mo	38.2	34.6	74.1	74.4	24	27	62.3	61.4	-	-
Node-positive primary	45.4	50	50.6	44.3	57	55	-	-	-	-
No. of lesions > 1	32.7	36.5	30.1	31.4	52	51	35.9	36	-	-
Largest met ≥ 5 cm	-	-	-	-	-	-	-	-	-	-
Chemotherapy	5-FU		5-FU		FOLFOX		5 –FU	FOLFIRI	5-FU + OX or 5-FU + Cap or FOLFIRI	5-FU + OX or 5-FU + Cap or FOLFIRI or + Cetuximab

¹n of eligible patients = 257, although only 234 patients had response rates analyzed; –: Represents data not assessable by authors; Surg: Surgery only; S + C: Surgery with additional chemotherapy; 5-FU: 5-fluorouracil based; FOLFOX: Fluorouracil, leucovorin, and oxaliplatin; FOLFIRI: Fluorouracil, leucovorin, and irinotecan.